Demand for Novo Nordisk's new weight-loss drug Wegovy outstripped early supply, analysts say

Demand for Novo Nordisk's new weight-loss drug Wegovy outstripped early supply, analysts say

Source: 
Fierce Pharma
News Tags: 
snippet: 

Novo Nordisk’s GLP-1 empire is on the ascent, courtesy of its diabetes stalwarts Ozempic and Rybelsus, plus its newly-approved obesity drug Wegovy. With momentum building—and facing "substantial" demand for its new weight loss med—the Danish drugmaker is dialing up its performance forecast for the year, CEO Lars Fruergaard Jørgensen said Wednesday.